Research Expert - Early Pharmaceutics

Evotec announces Chief Scientific Officer transition. Sep 29, 2026, 2:04 AM ET * Dr. Cord Dohrmann to step down as of September 30, 2026 * Search ongoing for a successor HAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ - Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company. Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said: "I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years. Throughout his tenure, he has played a significant role in strengthening the scientific excellence and innovation culture that Evotec is known for. With his strategic vision for emerging technologies and future scientific trends, Cord has helped establish key capabilities across our platforms, including our iPSC-based technologies and omics capabilities, which have further reinforced Evotec's scientific leadership. Looking to the future, the robust science infrastructure that Cord has built will be an essential component of Evotec's future growth and profitability." Dr. Cord Dohrmann, Evotec's outgoing Chief Scientific Officer, added: "The process of advancing new therapies from discovery to the clinic has evolved significantly over the past 16 years, and I have been privileged to contribute to that progress during my time at Evotec. I am grateful for the support and collaboration of the many colleagues I have worked with in that time and look forward to seeing Evotec's scientific expertise continue to create value for customers, partners and patients." Dr. Dohrmann has served as Chief Scientific Officer and Member of the Management Board since 2010. The search for his replacement is ongoing. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of around 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investor Relations and Media Contact Dr. Sarah Fakih EVP Head of Global Communications & Investor Relations [email protected] SOURCE Evotec SE NOTE: This content is not written by or endorsed by "WOWK", its advertisers, or Nexstar Media Inc.

Aptadir Therapeutics, a Milan-based biotech company developing RNA inhibitor-based therapeutics for genetic conditions, has closed a €40 million ($45 million) seed round. The financing was led by 4BIO Capital, with follow-on participation from EXTEND, the company's pre-seed investor launched by CDP Venture Capital SGR, Angelini Ventures, and Evotec SE. The funds will advance Aptadir's pipeline of RNA therapeutics, including its lead candidate CAP1-FMR1 for Fragile X Syndrome. The company's technology uses a new class of RNAs called DNMTs Interacting RNAs (DiRs) that can block aberrant DNA methylation at single gene level, potentially reversing abnormal gene silencing. The science originates from Beth Israel Deaconess Medical Center, the Italian Research National Council, and the Cancer Science Institute of Singapore. Additional investors include CDP Venture Capital, Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech, and Club degli Investitori.

Evotec stock holds near 52-week low as new T-cell alliance meets weak earnings. Published on 09/04/2026 at 08:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Evotec stock is trading just above its 52-week low, even after a fresh T-cell research alliance with Plectonic. Investors are weighing the collaboration against sharply lower second-quarter revenue and a projected operating loss for 2026. Evotec (ISIN DE0005664809) stock is trading close to its 52-week low, with shares at 3.25 EUR on Xetra as of September 4, 2026, even after the company announced a new T-cell research alliance targeting solid tumors according to an article on ad-hoc-news.de. New T-cell alliance with limited near-term cash impact. Evotec, the Hamburg-based drug discovery group, has entered a collaboration with biotech partner Plectonic Biotech to develop a novel T-cell engager approach for solid tumors, pairing Evotec's BiTco platform with Plectonic's LOGIBODY technology as reported by ad-hoc-news.de. According to the same report, the Plectonic agreement is the third partnership announced within weeks, following collaborations with Odyssey Therapeutics in autoimmune and inflammatory diseases and a preclinical development mandate from Niagen Bioscience for its NB4168 candidate, highlighting that Evotec's platforms remain attractive to biotech partners despite a challenging share price. Second-quarter figures show a sharp downturn. Fundamentals remain the key concern for investors. Evotec's latest quarterly figures for the three months to June 30, 2026 (second quarter 2026) show revenue of 143.5 million EUR for the April to June period, with first-half 2026 sales at about 300.1 million EUR, representing a 19.2 percent decline year on year according to ad-hoc-news.de. A detailed market overview from finanzen.ch confirms that in the quarter ended June 30, 2026, Evotec generated 143.48 million EUR of revenue, down 16.21 percent compared with 171.24 million EUR in the prior-year quarter, while loss per share widened to -0.26 EUR from -0.24 EUR a year earlier. In addition, adjusted EBITDA swung to a loss of 42.7 million EUR in the first half of 2026 according to the ad-hoc-news.de analysis, underscoring that profitability pressures have intensified even as the company continues to sign new collaborations. Guidance points to a full-year operating loss. The same ad-hoc-news.de article notes that Evotec's management has reaffirmed significantly reduced full-year guidance issued in July 2026, continuing to project an operating loss of up to 105 million EUR for fiscal year 2026, signaling that the current year is expected to remain loss-making despite the pipeline of partnerships. Analyst sentiment has weakened in response. According to the ad-hoc-news.de report, one financial portal cut its average price target for Evotec stock to 4.60 EUR from 5.67 EUR in late August 2026, lowering expectations by more than 1.00 EUR and reflecting a more cautious view of the company's ability to translate its platform deals into earnings. More data and background on Evotec. For additional regulatory filings, historical performance and long-term charts of Evotec, investors can consult the broader company topic pages and official disclosures. Stock near MDAX and TecDAX low despite bounce. Market data compiled by finanzen.ch shows that on September 3, 2026, Evotec shares gained 0.5 percent around midday to 3.32 EUR on Xetra, after opening the session at 3.31 EUR and reaching an intraday high of 3.37 EUR, with about 136,747 shares traded, placing the stock among the stronger names in the MDAX at that point. The same finanzen.ch overview states that Evotec, a TecDAX constituent, hit its lowest level in 52 weeks at 3.12 EUR on September 2, 2026, while the 52-week high of 7.30 EUR was recorded on October 27, 2025, meaning the current price is more than 50 percent below the peak and within about 6.2 percent of the recent low. According to the ad-hoc-news.de article, Evotec shares now trade at 3.25 EUR, only 3.6 percent above a 52-week low of 3.14 EUR set on September 2, 2026, and roughly 57 percent below a 52-week high of 7.75 EUR reached on November 5, 2025, highlighting how sharply valuation has compressed over the past year. Business model: discovery platforms and milestone potential. Evotec's business model centers on deploying its discovery and development platforms, such as the BiTco technology, to secure collaborations that can generate upfront payments, research funding, milestones and potential royalties over time according to the ad-hoc-news.de analysis. The recent sequence of deals with Plectonic, Odyssey Therapeutics and Niagen Bioscience illustrates that the company is actively leveraging its platforms across oncology, autoimmune and inflammatory indications, although both the ad-hoc-news.de report and the finanzen.ch earnings summary emphasize that near-term financial benefits remain limited while losses and revenue declines weigh on results. Evotec stock price level as of early September 2026. For retail investors, the key takeaway is that Evotec stock is currently priced near its technical floor, at 3.25 EUR per share on Xetra as of September 4, 2026 according to ad-hoc-news.de, only a few percent above the recent 52-week low in a TecDAX and MDAX environment that has seen more stable performance from other constituents. Evotec at a glance. * Company: Evotec SE * ISIN: DE0005664809 * WKN: 566480 * Ticker: EVO * Trading venue: Xetra (Germany) * Price (as of September 4, 2026): 3.25 EUR * Market capitalization: 75,200,000 USD (as of September 3, 2026, based on Evotec SE American listing data compiled by StockTitan) * Sector / Industry: Health Care / Biotechnology * Index membership: TecDAX, MDAX Follow Evotec on social platforms. Sponsored Ad Evotec stock: new analysis - 5 September. Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI. en | DE0005664809 | EVOTEC SE | boerse | 70053097 | bgmi